Endocrine Abstracts

Objectives: Graves’ hyperthyroidism is a frequent complication of alemtuzumab treatment in MS. We present the case of an MS patient who developed clinically and biochemically overt alemtuzumab-induced Graves’ disease, remitting 6 months after treatment with ocrelizumab and methylprednisolone pulse-therapy.Methods: A 49-year-old man diagnosed with active multiple sclerosis who had undergone alemtuzumab treatment, and developed Graves’ hyper...